Physician profile
Paul Dotherow
NPI 1376076794
$7,885.65
in general payments reported to CMS, 2019-2025
37 companies · $2,701 in 2025
The $2,701 reported for 2025 was more than what 85% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $116 · 2021: $565 · 2022: $687 · 2023: $1,451 · 2024: $2,366 · 2025: $2,701.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,496 · Education: $21.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,496.20 |
| Education | $21.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,393.08 | 2020-2025 | Skyrizi, Rinvoq, Viberzi |
| Takeda Pharmaceuticals U.S.A., INC. | $1,238.90 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $579.46 | 2023-2025 | Stelara, Tremfya, Simponi Aria |
| Gilead Sciences, INC. | $505.92 | 2020-2025 | |
| Pfizer INC. | $301.21 | 2021-2025 | |
| Genzyme Corporation | $246.12 | 2023-2025 | |
| Conmed Corporation | $196.20 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $173.21 | 2023-2025 | Dupixent |
| Organon LLC | $169.85 | 2023-2025 | Hadlima, Renflexis |
| Lilly USA, LLC | $163.68 | 2024-2025 | Omvoh |
| Ardelyx, INC. | $152.21 | 2023-2025 | Ibsrela |
| Medtronic, INC. | $149.91 | 2023 | Manoscan |
| Phathom Pharmaceuticals, INC. | $149.82 | 2023-2025 | Voquezna |
| Celgene Corporation | $133.98 | 2022-2024 | Zeposia |
| Madrigal Pharmaceuticals | $131.51 | 2024-2025 | Rezdiffra, Resmetirom |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Dotherow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.